Galapagos (NASDAQ:GLPG) Reaches New 1-Year Low at $29.45

Galapagos NV (NASDAQ:GLPG - Get Free Report)'s share price hit a new 52-week low during trading on Tuesday . The company traded as low as $29.45 and last traded at $29.49, with a volume of 16106 shares changing hands. The stock had previously closed at $29.80.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Bank of America restated an "underperform" rating and issued a $31.00 price target (down from $41.00) on shares of Galapagos in a report on Thursday, March 28th. Morgan Stanley assumed coverage on Galapagos in a report on Thursday, March 7th. They issued an "equal weight" rating and a $38.00 price target on the stock. Finally, StockNews.com lowered Galapagos from a "buy" rating to a "hold" rating in a report on Monday, March 18th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $34.50.

Galapagos Stock Down 1.0 %

The firm has a market cap of $1.94 billion, a P/E ratio of -12.88 and a beta of 0.25. The firm has a fifty day moving average of $34.72 and a 200-day moving average of $36.55.

Institutional Trading of Galapagos

Several institutional investors and hedge funds have recently bought and sold shares of GLPG. Wellington Management Group LLP increased its position in Galapagos by 3.9% during the fourth quarter. Wellington Management Group LLP now owns 495,217 shares of the biotechnology company's stock worth $20,131,000 after buying an additional 18,552 shares during the last quarter. GTS Securities LLC acquired a new position in Galapagos during the fourth quarter worth approximately $348,000. Voloridge Investment Management LLC increased its position in Galapagos by 653.2% during the fourth quarter. Voloridge Investment Management LLC now owns 56,159 shares of the biotechnology company's stock worth $2,283,000 after buying an additional 48,703 shares during the last quarter. OLD Mission Capital LLC acquired a new position in Galapagos during the fourth quarter worth approximately $1,381,000. Finally, Greenlight Capital Inc. grew its position in shares of Galapagos by 4.0% in the fourth quarter. Greenlight Capital Inc. now owns 162,578 shares of the biotechnology company's stock valued at $6,609,000 after purchasing an additional 6,200 shares during the last quarter. Institutional investors own 32.46% of the company's stock.

Galapagos Company Profile

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of?various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and uveitis.